Ion channels are pore-forming transmembrane proteins that allow the regulated flow of cations or anions across membranes. The International Union of Basic and Clinical Pharmacology (IUPHAR) Guide to Pharmacology 1 cur rently lists 145 genes for voltagegated-like ion channels 2 , 82 genes for ligand-gated ion channels 3 and 52 genes for so-called other channels 4
such as aquaporins, connexins or store-operated channels in humans. However, as many ion channels form homo mers or heteromers of two, three, four or five subunits -which addi tionally may interact with auxiliary proteins -the total number of possible ion channels that can be assembled from these genes and that serve very specific physiological functions is much larger. Ion channels currently constitute important drug targets for the treatment of type 2 diabetes, hypertension, epilepsy, cardiac arrhyth mia and anxiety, and many of the classical drugs on the World Health Organization (WHO) list of essen tial medicines, such as nifedipine (a voltage-gated cal cium channel (Ca V 1.x) inhibitor), amiodarone (which inhibits multiple channels, including voltage-gated potassium channels (K V )), phenytoin (a voltage-gated sodium channel (Na V ) inhibitor) and diazepam (a GABA A receptor activator) are ion channel modulators. A recent comprehensive analysis of molecular targets 5 estimated that 18% of small-molecule drugs exert their therapeutic effects through ion channels (see Supplementary Table 1 for a comprehensive list of clinically used drugs targeting human ion channels). It is noteworthy that these clinically successful examples are all small-molecule drugs that were developed long before their molecular targets were identified, solely by exploiting ex vivo and in vivo approaches. Following the initial registrations of these classic compounds between the early 1950s and early 1980s, the number of ion channel-targeting drugs increased quickly, arguably often because of 'me too' drug development around the original chemical structure and incremental property adjustments (most clearly illustrated by the dihydropyridine anti-hypertensives, the sulfonylurea type 2 antidiabetics and the benzodiazepine anxiolytics shown in Supplementary Table 1) .
On the basis of electrophysiological experiments, and especially with the introduction of patch-clamp technology 6 , the modes of action of the most important ion channel-targeting drug classes (Na V inhibitors, K ATP (inwardly rectifying potassium channel K ir 6.x) inhibitors and so on) were quite well established by around 1990
(ref. ). At the end of the cloning era in the late 1990s, the majority of ion channels were identified and revealed a complex picture with respect to subtypes, stoichiometry and pharmacology 8 . The exceptions were the voltage-gated proton channel (H V ), calcium-activated chloride channels (CaCCs) and volume-regulated chloride channels (VRACs), the stretch-activated and voltageactivated Piezo channel and the calcium release-activated calcium channel (Orai), which were cloned only a decade later. It specifically became apparent that even closely related subtypes, such as members of the K V 1 family, can 4 and Vladimir Yarov-Yarovoy 5 Abstract | Ion channels play fundamental roles in both excitable and non-excitable tissues and therefore constitute attractive drug targets for myriad neurological, cardiovascular and metabolic diseases as well as for cancer and immunomodulation. However, achieving selectivity for specific ion channel subtypes with small-molecule drugs has been challenging, and there currently is a growing trend to target ion channels with biologics. One approach is to improve the pharmacokinetics of existing or novel venom-derived peptides. In parallel, after initial studies with polyclonal antibodies demonstrated the technical feasibility of inhibiting channel function with antibodies, multiple preclinical programmes are now using the full spectrum of available technologies to generate conventional monoclonal and engineered antibodies or nanobodies against extracellular loops of ion channels. After a summary of the current state of ion channel drug discovery , this Review discusses recent developments using the purinergic receptor channel P2X purinoceptor 7 (P2X7), the voltage-gated potassium channel K V 1.3 and the voltage-gated sodium channel Na V 1.7 as examples of targeting ion channels with biologics.
have very different physiological functions and thus can provide highly variable therapeutic and adverse effect profiles. This realization initiated an explosion in the number of ion channel drug discovery programmes [9] [10] [11] [12] [13] dedicated to the development of subtypeselective small-molecule drugs that would be tailor-made to improve the therapeutic index (for example, Ca V 2.2 and Ca V 3 inhibitors for neurological indications such as stroke or pain without effects on Ca V 1 and thus no cardiovascular side effects; or GABA A α2/α3 receptor selec tive activators for an xiety without effects on α1-containing channels and therefore without sedative properties. Hand-in-hand with this progress, cloning, molecular and cell culturing techniques improved substantially, high-throughput automated ion channel assays were developed and all large pharmaceutical companies upgraded (often to several millions of chemical entities) and refined their chemical libraries 14, 15 . In the most streamlined versions, a complete screening campaign, including reporting on one or more subtypes, could be completed in just 2-3 months.
This tremendous and long-lasting effort across essentially the entire pharmaceutical industry should have been a leap forward with respect to improved ion channel medicines, but very few registrations have resulted from these efforts. For example, out of the K V channel modulator programmes we reviewed in 2009 (ref. 10 ), only one compound, the K V 7 activator retigabine (known as ezogabine in the US) for the treatment of pharmacotherapy-resistant partial epilepsies, made it to market in 2011, but was then withdrawn in 2017 by GlaxoSmithKline because of skin discolouration and suspected eye toxicity related to the slow accumulation of a coloured metabolite. It is especially sobering that even recent registrations are either based on long-known compounds (for example, the K V channel blocker 4-amino pyridine, registered in 2010 for multiple sclerosis 16 , and the GABA A receptor-activating molecule allo pregnanolone, registered in 2018 for postpartum depression) or were discovered in low-throughput phenotypic screening by combining organ preparations with animal model work (the hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel inhibitor ivabradine 17 ; registered in 2015). The only notable exception we could find is the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator ivacaftor (VX-770), which originated from a high-throughput membrane potential assay screen and which increases the open probability of wild-type and mutant CFTR 18 . For a list of the ion channel-targeting drugs approved in the past 10 years, see Table 1 .
Inspecting the reported clinical pipelines from major pharmaceutical and biotechnology companies does not substantially change the picture (Table 2) : one topical polyclonal antibody, three peptides and thirty-three small-molecule clinical programmes are currently reported; most are in phase I, a handful are in phase I/II and only two -SAGE-217, a synthetic GABA A receptoractivating neurosteroid for major depression, and gefapixant, a P2X purinoceptor 3 (P2X3) inhibitor for chronic cough -are in phase III. One compound, miro gabalin, an improved gabapentinoid that targets Ca V channels, is under registration in Japan for peripheral neuropathic pain. Furthermore, two of the phase II examples are repurposed compounds (seni capoc, an inhibitor of the calcium-activated potassium channel K Ca 3.1 for hereditary xerocytosis and Alzheimer disease, and gabo xadol, a GABA A receptor δ subunit-preferring
Patch-clamp technology
Patch-clamp is an electrophysio logical technique in which a glass pipette is sealed tightly to the cell membrane of an individual cell. In the most common voltage-clamp configurations, voltage across the cell membrane is controlled by the experimenter, and the resulting currents are recorded. Patch-clamp is considered the gold-standard in the ion channel field and has been automated for higher throughput. Even though small molecules will continue to be important for ion channel drug development in years to come, we are convinced that the role of ion channeltargeting biologics will increase and help revitalize ion channels as targets for drug development. Following on the heels of the G protein-coupled receptor (GPCR) field 19 , in which several dozen antibody programmes have advanced into clinical trials and antibodies targeting CC-chemokine receptor 4 (CCR4) or calcitonin gene-related peptide (CGRP) are on the market, the ion channel field is particularly excited about antibody approaches at present. This article discusses the current state of research into antibodies and peptides that target this complex and diverse group of molecules.
Challenges in targeting ion channels
Ion channels have long been regarded as difficult drug targets and three reasons have traditionally been given, particularly with respect to small-molecule drug discovery 10 . Those reasons are the technical difficulties in ion channel high-throughput screening, the lack of crystal structures to enable structure-based drug design and the challenges in achieving subtype selectivity, which must take into account stoichiometry of heteromeric channels, possible interactions with auxiliary subunits (a point often ignored in drug discovery) and, ideally, state or conformation selectivity. All these issues are also applicable to ion channel-targeted biologics. The first issue has been somewhat addressed with the development of ultra-high-throughput membrane potential or flux assay systems and automated electrophysiology platforms that are currently capable of running high-quality giga seal electrophysiological recordings in 48, 96 and 384 wells. However, we would like to posit that the specialized biophysical expertise that is necessary to expertly execute and analyse ion channel screens constitutes a real or sometimes perceived barrier to committing to an ion channel drug discovery programme, which, together with the fact that more resources in industry and academia have been dedicated to GPCRs than to ion channels, is probably responsible for the overall slower progress of the ion channel than the GPCR field. The second point, the lack of structures, is a deficiency that is currently being addressed by advances in structural biology (box 1) but again somewhat more slowly than in the GPCR field. The third point -obtaining relevant subtype and state or confirmation selectivity -remains a challenge for both the ion channel and the GPCR fields (although voltage-clamp electrophysiology, with its high temporary resolution and voltage control combined with fast application, should give ion channels an advantage) and requires very detailed understanding of the exact role and context of the target protein in the chosen disease indication.
Target specificity. Nearly all efforts within ion channel drug discovery and development previously focused on small molecules, which face the same general issues as almost all other small-molecule medicinal chemistry programmes, namely, optimizing pharmacokinetic properties 20 , avoiding toxicity owing to toxic metabolites 21 and finding chemical matter that ideally allows one to obtain strong composition of matter patents. However, ion channel drug discovery faces one key additional challenge: obtaining selectivity within ion channel families can be difficult to achieve because subtypes are often highly homologous. This is especially challenging for small-molecule drugs owing to their small sizes and therefore their limited number of interaction points with the target. The field of Na V inhibitors is particularly instructive: anti-epileptics, class I antiarrhythmics and local anaesthetics target Na V channels at a highly conserved site within the pore lumen formed by transmembrane segments of S6 in the third and fourth domains 22 . Thus, despite many years of drug development by many companies, all classical Na V -targeting drugs are essentially unselective, and their therapeutic value as systemically administered drugs relies solely on their strong state or use dependency, which favours binding to channels in pathologically depolarized or excessively firing cells.
State-dependence in this context means that a drug preferentially binds to one of the conformational states (closed, open or inactivated) that an ion channel undergoes during its gating cycle (fIg. 1a) . For voltage-gated channels such as Na V , Ca V and K V , the occupancy of these states strongly depends on the membrane potential, which means that drug development programmes focused on targeting neuronal ion channels must decide which state of the channel to target. For example, for Na V channels, the most desirable state to target is generally assumed to be the open or inactivated state, whereas it might be better to target the closed state for a K V channel opener. If neuronal ion channels are expressed in HEK293 or CHO cells, their voltage-sensing domains (VSDs) are exposed to relatively depolarized resting membrane potentials (around -40 mV) instead of the relatively hyperpolarized resting membrane potentials (around -70 mV) of neurons. This means that in flux or binding assays, which do not allow control of the membrane potential, the VSDs will tend to be in the thermodynamically favoured 'up' state that is present in open or inactivated states of the channel, which makes it difficult to identify molecules that bind to the 'down' state of the VSD that is present in the closed state (fIg. 1a) . One of the major advantages of using manual or high-throughput patch-clamp electrophysiology for ion channel drug screens is that the membrane potential can be precisely controlled to capture the desired state of the channel.
The Na V channel family contains nine functional subtypes 23 , Na V 1.1 to Na V 1.9. Na V 1.1 is expressed in fast-spiking interneurons of the brain, in which loss of Na V 1.1 function causes Dravet syndrome 23 . Na V 1.1
Giga seal electrophysiological recordings electrophysiological recordings in which a glass pipette is sealed so tightly to the membrane of a cell that it creates a giga seal, meaning a >10 9 ohm leak resistance. This causes low noise and excellent mechanical stability, which allows recording of single ion channels in patches of membranes as well as of all channels in a cell.
NATuRe RevIewS | DRug DISCoveRy has recently been shown to regulate the mechanical excitability of visceral nerves in the gut 24, 25 . Na V 1.2 is the predominant brain isoform and, together with Na V 1.6, is a major target for anti-epileptic drugs. Na V 1.5 is the main cardiac channel and the target for class I antiarrhythmics, whereas the analgesic effects of local anaesthetics are mediated by several channels, including Na V 1.7, Na V 1.8 and possibly Na V 1.9, which are preferentially expressed in sensory nerves 26 . Na V 1.7 and Na V 1.8 have clear pain phenotypes in humans, as loss-of-function and gain-of-function mutations in Na V 1.7 result in congenital insensitivity to pain 27 and primary erythromelalgia 28 , respectively, whereas gain-of-function mutations of Na V 1.8 may cause painful peripheral neuropathy 29 . Despite convincing preclinical effects of unselective Na V blockers in animal pain models and the effective use of the anti-epileptic carbamazepine in trigeminal neuralgia pain 30 , existing Na V -inhibiting drugs are not optimal for general treatment of severe pain disorders owing to their unselective modes of action. Several companies (including Genentech, Biogen, Amgen, Pfizer and Bayer) are or have been developing highly subtype-selective and potent small-molecule inhibitors of Na V 1.7 by targeting binding to a site in the domain IV voltage sensor, which is responsible for channel inactivation, rather than the classical local anaesthetic site in the pore lumen [31] [32] [33] . On the basis of the currently published structures, this is achievable with a series of close analogues that all have a conserved aryl-sulfonamide core structure, often dramatically called the 'warhead' . For example, Genentech has published an X-ray structure 31 of the aryl-sulfonamide GX-936 bound to a receptor site within the Na V 1.7 fourth VSD (fIg. 1b) . Unfortunately, one of these small molecules, the clinical phase II compound PF-05089771 (fIg. 1b) , recently failed in patients with painful diabetic neuropathy 34 , which led Pfizer to stop further development. Bankar et al. suggested that this failure possibly reflected insufficient Na V 1.7 targeting in the clinical study and recommended the evaluation of acyl-sulfonamides with improved physio chemical and pharmacological properties 35 , including a longer residence time on the target 36 . Because PF-05089771 is intentionally peripherally restricted, compounds with improved blood-brain barrier (BBB) penetrability in humans might better engage Na V 1.7 channels that are expressed close to or on the bouton of the dorsal root ganglion (DRG)-neuron dorsal horn synapse. Another reason for the apparent failure of some Na V 1.7 blockers could be interactions between the α subunit and β subunits that occur in the native channel in DRG neurons, which were not recaptured in heterologous screening systems that used only the α subunit. Sokolov et al. recently demonstrated that co-expression of Na V 1.7 with the glycosylated form of the sodium channel β3, an auxiliary subunit that is upregulated in injured human sensory neurons 37 and in DRGs in rat pain models 38 , makes Na V 1.7 less sensitive to several state-dependent Na V blockers 39 . Whether this would also be the case for the aryl sulfonamides was not investigated in the study, but it is interesting to speculate, on the basis of the recently solved structures of the human and electric eel Na V 1.4-β1 complexes 40, 41 , that β subunits could prevent the binding of small molecules or antibodies to Na V 1.7. Finally, it is possible that a slightly broader selectivity that includes the other DRG channels, Na V 1.8 and Na V 1.9, may be needed. Vixotrigine (also known as raxatrigine; Biogen), which is still active in phase II despite a recent failure in painful lumbo sacral radiculopathy, has a different structure from the other Na V 1.7-targeting compounds (fIg. 1b) , passes the BBB and is reportedly less subtype-selective than the aryl-sulfonamides 42 . An interesting and highly challenging result of the selectivity issues with small molecules is that considerable domain homology exists between even remotely related ion channel families. Even highly subtype-selective compounds may therefore have off-target effects on other ion channels, such as the cardiac delayed rectifier hERG (also 
) | Ion channel-targeting drug development candidates currently in clinical trials
NATuRe RevIewS | DRug DISCoveRy known as K V 11.1), inhibition of which may cause ventricular fibrillation and sudden death 43, 44 . Unfortunately, hERG binds numerous small-molecule chemotypes with remark able promiscuity 43, 45 , and thousands of otherwise useful drug candidates have been filtered out because they alter hERG activity 43, 45 . Another selectivity-related aspect that is worth mentioning is species specificity. Although it has been incredi bly challenging to achieve subtype selectivity between closely related human channels such as within the Na V or Ca V family or for certain GABA A receptor or nicotinic acetylcholine (nACh) receptor subtypes, species-selective small molecules seem to be more easily attainable. Neuro active insecticides such as the Na V -blocking pyre throids, the nicotinic receptor channel-activating neonicotinoids and the GABA A receptor-blocking poly chlorocyclohexanes and fiproles have extremely low acute mammalian toxicity 46 . Examples of species-specific ion channel modulators used in human medicine are the anti virals amantadine and rimantadine, which target the M2 proton channel, a member of the so-called viro porin ion channel family that is specific to viruses and has very little homology to prokaryotic or eukaryotic ion channels 47 . However, species differences in sensitivity to drugs among mammals can also be very problematic for translational drug discovery, as exemplified by the insensitivity of the rat isoform of Na V 1.7 towards inhibition by the aryl-sulfonamide inhibitor AMG-8379 (ref.
33
).
Biologics versus small molecules. Even though biologics have their own well-known challenges, such as poor membrane permeability and the risk of triggering adverse immune reactions, they constitute an attractive alternative to small molecules. First, they have much higher binding selectivity (approaching true specifi city), to both subtypes and off-targets, than is generally possible with small molecules. Additionally, antibodies and peptides are metabolized as part of the normal protein dynamics of the body and thus do not have the drug-drug interactions and metabolism-mediated toxicity that are always a risk with small molecules. Taken together, these two advantages are often considered to be responsible for the overall higher success rate of new molecular entity biologics (13.2%) versus small mol ecules (7.6%) for progression from phase I to US Food and Drug Administration (FDA) approval 48 . The feasibility of targeting ion channels with biologics has been amply demonstrated in the natural world. Venomous animals have developed myriad highly potent and selective peptides that can both inhibit and activate ion channels and that have been incredibly useful in probing ion channel structure-function relationships. Similarly, autoantibodies from patients can inhibit ion channel function and acutely transfer disease to experimental animals. For example, most cases of myasthenia gravis, a disease that leads to skeletal muscle weakness, are caused by pathogenic antibodies that bind to nACh receptors at the neuromuscular junction 49 , and a related condition, Lambert-Eaton myasthenic syndrome, is triggered by antibodies against P-type and/or Q-type Ca V channels on presynaptic nerve terminals 50 . For both diseases, some autoantibody clones directly block the respective channels in electrophysiological experiments, whereas other antibodies can activate complement or induce channel internalization 49, 50 . Another example of a neurological disease characterized by the presence of ion channel-specific autoantibodies is neuromyelitis optica, in which most patients test positive for aquaporin 4 antibodies 51 .
Ion channel-targeted peptides
Since the development of exenatide 52 , a 39-amino-acid glucagon-like peptide 1 (GLP1) agonist isolated from the venom of a lizard, and its approval in 2005 as an injectable treatment for type 2 diabetes, peptides are increasingly being considered as viable therapeutics. The FDA has approved over 60 peptide drugs (predominantly targeting GPCRs for the treatment of meta bolic disease and for oncology 53 ), around 140 peptides are in clinical trials, and another 500 are in preclinical development 53 . The global peptide therapeutic market is estimated to be close to US$25 billion in 2018 (ref.
54
Venoms are a rich source of bioactive peptides with therapeutic potential [55] [56] [57] [58] . Over eons, more than 100,000 venomous creatures -arthropods (scorpions, spiders, bees, centipedes and wasps), cnidarians (sea anemones and jellyfish), molluscs (cone snails), annelids (fire worms and parasitic worms) and vertebrates (snakes, lizards, frogs and mammals) -have used their toxic cocktails to engage important biological targets. These cocktails are deployed as weapons to immobilize or kill prey or as a defence to deter predators or microbial invaders. Over 10 million bioactive peptides and proteins are estimated to be present in animal venoms, and their immense chemical diversity is unrivalled by
Box 1 | Recent progress for ion channel structure-based drug design
In the past 5 years, an increasing number of ion channel structures have become available through advances in cryoelectron microscopy (cryoem), such as improvements in microscope design and imaging hardware as well as enhanced image processing, which allow the reconstruction of 3D structures from a large number of single particle 2D projection images even in the presence of structural and conformational hetero geneity 183 . Although many cryoem structures are not of high enough resolution for true structurebased drug design because they cannot identify the possible locations of hydrogen bonds or salt bridges, Rosetta computational structure refinement can be used to improve atomic details of cryoem structures with 3-5 Å resolution 184 . For example, in the voltagegated sodium channel (Na v ) field, both traditional Xray and cryoem structures now provide highresolution structural templates for structurebased design of novel small molecules, peptides and antibodies. However, although many of the structures contain fully resolved extracellular loops, a remaining challenge is how to stabilize the extracellular loop regions in native conformations for immunization without having to produce large quantities of fulllength protein.
Three sets of examples of Na v channel structures illustrate these recent advances. First, an Xray structure of a human Na v 1.7-bacterial Na v Ab chimaera 31 with a picomolar affinity drug bound to the domain Iv voltage sensor constitutes an attractive modelling template for targeting the voltage sensor with small molecules or peptides. Further, all human Na v channels have unique sequences in the extracellular loop regions within the voltagesensing and poreforming domains. However, these loops have been difficult to stabilize in structures. Two recent cryoem structures of the human Na v 1.4 (ref.
41
) and American cockroach Na v PaS 185 with a small molecule and/or a peptide toxin bound have all extracellular loops resolved in the pore and voltage sensor domains. Finally, the cryoem structure of the electric eel Na v 1.4 (ref.
40
) has all extracellular loops in the pore domain resolved. The gating charge-carrying arginines in the S4 segment are represen ted by + signs. Key conformational changes in the Na V channel during gating between closed, open and inactivated states are highlighted by transmembrane movement of the S4 segment and lateral movement of the carboxy-terminal part of the S6 segment. Inactivation of Na V channels can be either fast and involve one of the cytoplasmic inter-repeat loops plugging the inner vestibule 8 or slow and involve a rearrangement of the selectivity filter 8 . b | A representation of small molecule-binding sites within Na V is shown. A transmembrane view of the interaction of the Na V channel with pore-bound (lidocaine; purple space-filled representation) and voltage sensor-bound (GX-936; light blue space-filled representation) small-molecule drugs is depicted. The Na V channel structure is shown in ribbon representation and is based on the electric eel Na V 1.4 channel structure 40 (Protein Data Bank identifier: 5XSV) and the Na V Ab-Na V 1.7 chimaera structure 31 synthetic libraries. The ability of these animals to kill with tiny amounts of powerful venom has inspired both fascination and fear in humans, and snakes and scorpions were deified in the ancient world 59 . Traditional medicines in China, India, Greece and the Middle East have used this vast bioactive resource for medicines for centuries. In modern times, there has been an increasing interest in exploiting this extensive and somewhat untapped pharmacopoeia using proteomic and genomic approaches 55, 58 . As of today, six venom-derived peptides, including the Ca V 2.2-blocking ziconotide (also known as Prialt), have been approved by the FDA, about a dozen are in clinical trials and several more are in preclinical development 55, 58 . Below, we discuss the ion channel-targeting peptides in more detail by focusing on peptides that have entered clinical trials or started preclinical development in the past 10 years.
Ion channels are frequently targeted by peptide toxins. Starting in the 1960s, animal toxins were used as molecular tools to investigate ion channels [60] [61] [62] . Many of these toxins have disulfide-constrained architectures that enhance their stability and protease resistance and permit tremendous variations in primary sequence without perturbation of the 3D fold ( Supplementary Fig. 1 ). These characteristics make peptides with disulfide-rich scaffolds attractive as therapeutics. fIgure 2a highlights the channel-modulating peptides that are discussed below. Many peptides are pore blockers [56] [57] [58] that bind at the extracellular entrance to the pore of the channel (external vestibule) and occlude the ion conduction pathway (fIg. 2b) . Others bind to the voltage sensor of the channel and alter channel gating (fIg. 2b) .
Channel-modulating peptides for the management of pain. The opioid crisis in the US has spurred efforts to develop non-opioid drugs for chronic pain, but many of these efforts have failed. A notable exception is ziconotide, a peptide derived from the venom of fish-hunting cone snails 63 , which was approved by the FDA in 2004. The development of this therapeutic agent began in the 1980s, when ω-conotoxin GVIA from Conus geographus and ω-conotoxin MVIIA from Conus magus (fIg. 2a) were shown to block Ca V channels in the nervous system but not in muscle [64] [65] [66] . The neuronal calcium channel was later defined as the N-type Ca V 2.2 channel. These peptides decrease neurotransmitter release from nociceptive afferent nerves that terminate in the dorsal horn of the spinal cord. The peptide that advanced to the clinic was native ω-conotoxin MVIIA (subsequently called ziconotide) 63 . It is administered intrathecally through an implanted pump because it does not cross the BBB. Ziconotide is efficacious when administered as a single therapeutic but is increasingly combined with an intra thecal opioid for the management of refractory chronic and cancer pain. Recent guidelines also recommend ziconotide as a first-line agent for neuropathic and nociceptive pain. Wider clinical use of ziconotide is impeded by its somewhat high cost, narrow therapeutic window and the requirement for an intrathecal pump 63, 67 . Another ion channel that has been suggested as a pain target based on genetic studies is Na V 1.7 (refS 27, 28 ).
μ-Theraphotoxin-Pn3a, a peptide from the South American tarantula Pamphobeteus nigricolor (fIg. 2a) , blocks Na V 1.7 with picomolar affinity and selectivity over other Na V channels 68 . The peptide is analgesic in rodent pain models when coadministered with sub-therapeutic doses of opioids but displays no analgesic activity when administered on its own 68 . A broad lack of analgesic activity was also found for the selective Na V 1.7 inhibitors PF-04856264 and phlotoxin 1 (ref.
68
Amgen recently engineered AM-8145 and AM-0422, two peptides based on the JzTx-V toxin (from the tarantula Chilobrachys guangxiensis) that selectively inhibit Na V 1.7 (ref.
69
). As mentioned above, in a recent human trial, the peripherally restricted, Na V 1.7-selective small molecule PF-05089771 did not significantly reduce pain scores compared with placebo 34 . Taken together, these results suggest that selective Na V 1.7 inhibitors may need to be administered with a sub-therapeutic dose of an opioid to achieve adequate analgesia [70] [71] [72] . The nACh receptor that contains the α9 and α10 subunits (α9α10 nACh receptor) is also considered a therapeutic target for pain 73 . The α-conotoxins Vc1.1 and RgIA from the cone snails Conus victoriae and Conus regius, respectively (fIg. 2a) , antagonize α9α10 nACh receptors 74, 75 . A second mechanism of action that has been suggested for these peptides is agonism of GABA B receptors and resulting inhibition of Ca V 2.2 via interaction with the G protein βγ subunit dimer 76 . Vc1.1 was effective in rodent models of pain 77 and advanced to phase II clinical trials, where it failed, possibly because it was less potent on human than rat α9α10 nACh receptors 58, 63, 78 , another example of the translational challenges that arise because of mammalian species differences. RgIA-4, an analogue of RgIA with high affinity for both rodent and human α9α10 nACh receptors and no activity on GABA B receptors, suppresses rodent cancer chemotherapy-induced neuropathic pain 58, 63, 79 and is currently in preclinical development.
P2X3 receptors are being targeted with small mo lecules for endometriosis-associated pain (Table 2) . These receptors are also inhibited by purotoxin-1 (PT1), a 35-amino-acid peptide from the venom of a wolf spider of the genus Geolycosa that slows recovery from desensitization following channel activation with ATP and reduces hyperalgesia in rat models of inflammatory pain 80 . Analogues of PT1 or related peptides, if optimized for specificity, potency and stability, could be advanced for pain indications.
Channel-modulating peptides for cancer therapy. Chlorotoxin (fIg. 2a) , a peptide from the death stalker scorpion Leiurus quinquestriatus hebraeus, was initially reported to inhibit small-conductance chloride currents in epithelial cells, astrocytomas and gliomas [81] [82] [83] [84] but was later found to also bind to matrix metallo proteinase 2 (MMP2) on glioma cells 85 and not to block volume-activated, cyclic-ATP-activated or calcium-activated chloride channels 86 . The molecular identity of the putative chloride channel blocked by chlorotoxin is therefore still undetermined. Phase I clinical trials a decade ago showed that an 131 I-radiolabelled analogue was safe following intraven ous administration for high-grade glioma, but the www.nature.com/nrd compound was not advanced further (ClinicalTrials.gov identifier NCT00733798). However, there are currently efforts underway to use chlorotoxin-based fluorescent dye conjugates as a 'tumour paint' to help visualize gliomas 87 , and one analogue, tozuleristide (BLZ-100) 88 , was tested in a phase I study (NCT02234297) in 2016, with a new phase II/III study about to start (NCT03579602) in paediatric patients with central nervous system (CNS) tumours in whom fluorescent-labelled chlorotoxin will be assessed with an imaging system. Transient receptor potential channel (vanilloid) TRPV6 is overexpressed in ovarian, breast, prostate, colon and thyroid cancers and has been implicated in tumour progression 89 . SOR-C13, a carboxy-terminal truncation of a longer, 54-residue paralytic peptide called soricidin from the short-tailed shrew (Blarina brevicauda), blocks TRPV6 at low nanomolar concentrations and suppresses tumours in xenograft models of ovarian and breast cancer 58, 90 . Fluorescently labelled (SOR-C27-Cy5.5) and super-paramagnetic iron oxide-conjugated analogues (SPIO-(SOR-C27)) of soricidin were used to visualize ovarian tumours in vivo in mouse models 90 . In a phase I trial in 23 patients with cancers of epithelial origin, SOR-C13 stabilized disease, suggesting that this peptide has antitumour activity 91 , but it caused grade 2-3 dose-related hypocalcaemia and atrial fibrillation in a quarter of patients 91 . Soricimed, the company developing SOR-C13, currently seems to be focusing on second-generation peptide-drug conjugates.
Rg1A
Channel-modulating peptides for neurological diseases. The acid-sensing ion channel ASIC1a, a key mediator of acidosis-mediated neuronal damage in cerebral ischaemia, is widely regarded as a potential therapeutic target for the treatment of ischaemic stroke 92 . π-Hexatoxin-Hi1a (Hi1a), a peptide from the Australian funnel-web spider Hadronyche infensa (fIg. 2a) , delays ASIC1a channel activation by binding to an acidic pocket that is critical for proton gating of the channel 93 .
In rodent stroke models, Hi1a attenuates brain damage and improves behavioural outcomes even when administered intracerebroventricularly 8 hours after stroke onset 93 . Intravenous and intranasal routes are currently being trialled in mice.
As previously mentioned, Na V 1.1 is localized in fast-spiking inhibitory neurons in the brain, and a loss-of-function mutation in Na V 1.1 is thought to cause epilepsy in Dravet syndrome owing to reduced inhibitory neurotransmission. The peptide Hm1a from the spider Heteroscodra maculata (fIg. 2a) activates and slows inactivation of Na V 1.1 at nanomolar concentrations 24 . In mice carrying the human R1407X nonsense mutation in Na V 1.1, Hm1a rescued the collapse of action potentials in inhibitory interneurons without affecting excitatory neurons 94 . Intracerebroventricular delivery of Hm1a reduced seizures and postictal mortality in a mouse model of Dravet syndrome 94 . Further development of Hm1a would require microinfusion pumps similar to those used for ziconotide delivery or microfluidic ion pumps that electrophoretically pump ions across an ion exchange membrane and thereby deliver the peptide without fluid 95 .
Channel-modulating peptides for treatment of autoimmune diseases. Potassium channels were discovered in T lymphocytes in 1984 (refS 96, 97 ). Two potassium channels, the voltage-gated K V 1.3 and the calcium-activated K Ca 3.1 channel, promote calcium entry into lymphocytes through store-operated calcium release-activated calcium (CRAC) channels (comprising Orai and stromal interaction molecule (STIM)) by providing a counterbalancing cation efflux 98, 99 . Blockade of these channels therefore suppresses T lymphocyte activation. Differential expression of these channels allows preferential suppression of terminally differentiated effector memory T (T EM ) cells, which contribute to the pathogenesis of numerous autoimmune diseases, with specific K V 1.3 inhibitors 100 . The ShK peptide from the sea anemone Stichodactyla helianthus (fIg. 2a) blocks K V 1.3 with picomolar affinity but also displays high affinity for neuronal potassium channels 101, 102 . An extensive structure-activity relationship programme led to the development of ShK-186 (dalazatide), an analogue with picomolar affinity for K V 1.3 and 100-fold to 1,000-fold selectivity for K V 1.3 over related channels 103, 104 . Sustained high picomolar levels of ShK-186 are achieved in plasma following subcutaneous injection. Owing to its long circulating half-life, ShK-186 is effective in rodent models of multiple sclerosis, rheumatoid arthritis and atopic dermatitis when administered every 2-3 days 104, 105 . In phase I trials in healthy human volunteers, no electro cardiogram changes were observed, and no severe or life threatening adverse effects were noted. In a phase Ib trial in patients with plaque psoriasis, dalazatide administered twice weekly by subcutaneous injection significantly reduced the psoriasis area and severity index in nine of ten patients 106 . This peptide caused temporary mild grade 1 hypoesthesia and paraesthesia involving the hands, feet or perioral area in the majority of patients 106 , possibly because dalazatide is cleaved into a product that is less specific for K V 1.3 (refS 103, 104 ). Plans for a phase II trial in the orphan disease inclusion body myositis 107 are on hold owing to financial constraints.
Other efforts have focused on improving in vivo pharmacokinetic properties of K V 1.3-blocking peptides. PEGylation of the scorpion peptide HsTx1[R14A] prolonged the plasma circulating half-life of this peptide in rodents and resulted in sustained efficacy in rodent models of multiple sclerosis and rheumatoid arthritis 108 . By screening a combinatorial ShK peptide library, novel analogues were identified that, when fused to the carboxy-termini of the crystallizable fragment (Fc) of immunoglobulin G1 (IgG1-Fc), retained picomolar potency, effectively suppressed in vivo delayed-type hypersensitivity and exhibited a prolonged circulating half-life 109 . Other approaches to target ion channels in autoimmune diseases include engineering another scorpion toxin into a humanized antibody to achieve picomolar affinity for K V 1.3 and long plasma half-life 110 and the development of novel formulations that achieve satisfactory blood levels of peptide inhibitors following buccal or pulmonary delivery 111, 112 . Scientists at Amgen generated the derivative ShK[Q16K] by brute-force structure-activity-based studies; weekly administration of a polyethylene glycol (PEG)-conjugated version of this peptide sustainably reduced plasma cytokine levels in primates and was efficacious in a rat model of multiple sclerosis 113 . A group at Janssen created half-life-extending Fc or albumin fusion proteins 114 with the α-KTx3 scorpion toxin OsK1 (α-KTx3.7) and tested them in mini-pigs. However, both companies subsequently seem to have dropped K V 1.3 as a target, likely on the basis of the previous observation 100 that the efficacy of K V 1.3 blockers depends on the strength of T cell stimulation and that K V 1.3 inhibition is therefore immunomodulatory rather than immunosuppresssive 115, 116 .
Postictal
The state or period after a seizure (time from the ending of an epileptic event until full mental recovery is achieved).
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Other channel-modulating peptides. The μ-conotoxin CncIIIC from the cone snail Conus consors (fIg. 2a) , which blocks Na V 1.4 and therefore has myorelaxant and analgesic properties 117 , is marketed by Activen as XEP-018, a topical cosmetic cream to reduce periocular wrinkles 58, 118 . SYN-Ake, an analogue of the peptide waglerin-1 from the south-east Asian temple viper Tropidolaemus wagleri, blocks muscle nACh receptors and modulates GABA A receptors 119 , and is being developed as an alternative dermaceutical to Botox for wrinkles 58 . Lastly, αCT1 (ACT1), a peptide based on the last nine amino acids of the carboxy terminus of connexin 43, a gap junction channel often found at the edge of wounds and associated with poor wound healing 120 , has been shown in multiple phase II trials to reduce mean ulcer area for chronic neuropathic foot 121 and venous leg ulcers 122 . Granexin gel is currently being tested in a phase III trial (NCT02667327) for diabetic foot ulcers, which affect roughly 15% of the global diabetic population.
Extending the plasma half-life of peptides. One weakness of peptide-based drugs is their short in vivo half-life owing to rapid renal elimination. This drawback can often be overcome by increasing the effective molecular mass of the peptide via conjugation to create so-called biobetters 123 . As discussed for several examples above, ion channel-targeting peptides have been conjugated to PEG, large proteins (for example, human serum albumin) or protein domains (for example, antibody Fc domain) or engineered into the complementarity-determining region (CRD) of humanized antibodies to generate fusion proteins 124 . Strategies to enhance peptide stability include peptide backbone cyclization, disulfide bridge modification, residue substitutions, peptide stapling 125 and computational design of hyper-stable constrained peptide scaffolds 126 . Backbone cyclization of the α-conotoxin RgIA enhanced its stability in human serum without perturbing the structure or function of the peptide [127] [128] [129] [130] . However, cyclization of APETx2 decreased its activity on ASIC3 despite enhanced stability 131 . In the α-conotoxin Vc1.1, disulfide bridges have been replaced by non-reducible dicarba linkages or have been eliminated and the core of the peptide stabilized by residue substitutions near the removed bridges 132, 133 . Both strategies improved stability and oral bioavailability of Vc1.1 but reduced activity. Stapling technologies have also been successful for stabilizing peptides that target N-methyl-d-aspartate (NMDA) receptors 134 . Thus, several post-translational methods can be used to augment stability, improve circulating half-life and even achieve oral bioavailability. The need for half-life extension, however, will depend on a number of factors, including the route of administration, the nature of the disease and whether the drug is intended for acute or chronic use. Some venom peptides are exceedingly stable in plasma, whereas others depot after cutaneous injection (for example, dalazatide 104 ). For chronic diseases such as diabetes and persistent pain, daily injectables are likely to be tolerated by patients, and therefore half-life may not be as critical. Exenatide, with an elimination half-life of 140 minutes, requires twice daily injection in patients with diabetes and has peak sales approaching $1 billion per year.
Using peptide-channel interactions to guide the design of peptidomimetics or small-molecule inhibitors. Many groups have exploited the understanding of peptidechannel interactions to design channel-modulating peptidomimetics. The earliest attempt to design a peptidomimetic of the sea anemone ShK peptide resulted in a million-fold loss in potency against K V 1.3 (ref.
135
). More recently developed peptidomimetic four-arm ethyl ene glycol-conjugated star polymers based on scorpion toxins have achieved nanomolar potency against K V 1.3 (ref.
136
). Peptidomimetics have also been designed to target connexins, neuronal Ca V 2.2 137, 138 and the β2 subunit of cardiac L-type (Ca V 1.2) calcium channels 139 .
In the 1990s, high-throughput screens using 125 I-charybdotoxin competitive binding assays led to the discovery of several small-molecule inhibitors (WIN-17317-3 and CP-339,818) with nanomolar potency against K V 1.3 [140] [141] [142] . However, although charybdotoxin bound in the outer vestibule of the channel, these small molecules likely bound in the inner chamber below the selectivity filter. Displacement of the radiolabelled peptide by these small molecules was due to a trans pore effect. Similar transpore inhibition of 125 I-charybdo toxin competitive binding to the large-conductance K Ca 1.1 channel was seen with indole diterpenes 143 . Radiolabelled-peptide-toxin binding assays have subsequently fallen out of favour for screening, and more recent high-throughput screens have used thallium flux or dyes that sense membrane potential or calcium.
Ion channel-targeted antibodies and nanobodies.
There are currently more than 60 approved therapeutic antibodies on the market, predominantly in the areas of oncology, autoimmunity and inflammatory disease, and approximately 550 antibodies are estimated to be in various stages of clinical development 144 . However, ion channel antibody discovery and development have lagged far behind, and only one antibody -a sheep polyclonal antibody (BIL010t; Biosceptre) that targets a non-functional form of P2X7 and is formulated as a topical ointment for the treatment of basal cell carcinoma -has reached human clinical trials thus far 145 . Venom peptides have long been recognized as superior to small molecules in terms of their potency and selectivity for ion channels, but targeting channels with equally selective antibodies has recently generated intense interest, mostly driven by the highly desirable pharmacokinetic characteristics of immunoglobulins compared with peptides, which result in a much lower dosing frequency. However, antibodies also have unique modes of action. Small molecules and peptides usually act by directly blocking ion flux through the open channel or by interfering with the gating processes, which can be either positive (activators) or negative (inhibitors), and therefore affect channel function on the microsecond to millisecond timescale (for example, use-dependent inhibition of Na V channels by classical small-molecule anti-epileptics). Antibodies can also work by occluding of the ion channel pore or allosterically inducing gating effects, but in addition, they can be engineered with enhanced Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, complementdependent cytotoxicity, antibody-dependent cellular phagocytosis or fcrn-mediated transcytosis. Furthermore, antibodies can carry toxic or radioactive payloads to target cells that are relevant to particular diseases 144, 146 . Thus, antibodies can potentially exert their modulating effect through one or a combination of mechanisms, including Fc-mediated depletion, internalization of ion channelantibody complexes 147 and/or modulation of ion channel behaviour with a conjugated peptide or small-molecule toxin -features that may also be enhanced by bivalent avidity effects.
The above-mentioned role of anti-ion channel autoantibodies in autoimmune diseases 148 and success in generating functional polyclonal antibodies against multiple ion channel targets 149 provided strong evidence for the feasibility of generating functional monoclonal antibodies (mAbs). However, overall progress in ion channel mAb discovery has been slow because of major technical challenges that seem to be somewhat target-specific. Indeed, ion channels and other multi-pass membrane proteins have recently been ranked among the 'high-hanging fruit' in terms of antibody drug discovery 144 . For example, although many ion channels share common structural motifs based around transmembrane and pore-forming domains, the surface topography of ion channels -where antibodies would be predicted to bind and exert their effects (the extracellular epitope target area) -can be quite different between ion channel families. For example, for members of the ASIC and P2X families, extracellular amino acids constitute approximately 68% and 48%, respectively, of the total protein 3 . Conversely, voltage-gated ion channels 2 such as Na V family members have far fewer amino acids exposed to the extracellular space (approximately 15%). Therefore, it is not surprising that reports of successful mAb programmes have tended to describe the discovery of functional antibodies targeting AISC and P2X and not Na V . The relative lack of immunogenicity of small surface loops, the high amino acid conservation among orthologues (which leads to immunological tolerance in host animals) and a scarcity of robust sources of recombinant ion channel protein to enable large scale antibody discovery programmes further complicate drug discovery against these targets.
Nevertheless, several strategies have successfully generated mAbs that inhibit ion channel function: the simplest approaches use antigenic peptides derived from ion channel extracellular domains. A particularly popular tactic has been targeting the pore-forming E3 loop of six-transmembrane-domain-containing K V , Na V or TRP channels using peptide antigens, with the rationale that antibody binding to this region will inhibit ion flow. This approach has been predominantly successful in generating polyclonal antibodies that block channel function 149 , although it has also been used to generate functionally blocking mAbs targeting K V 10.1 (ref. 150 ) or the T cell calcium influx channel Orai1. Using a peptide from the second extracellular loop of Orai1, a group at Amgen generated mAbs that inhibit CRAC current 151 , and a group at Novo Nordisk produced mAbs that inhibit calcium influx in T cells, suppress T cell proliferation and cytokine production and showed efficacy in a mouse model of graft-versus-host disease induced by human T cell transfer, presumably by inducing Orai1 internalization 152 . Channel internalization is also the mechanism of action of a mAb generated against purified peptide antigens from the first extracellular domain of human two P domain potassium channel K 2P 9.1 (KCNK9); the mAb inhibits tumour growth and metast asis in mouse cancer xenograft models 153 . However, isolating mAbs using peptide-derived strategies is not always successful, presumably because peptide antigens, although abundant and inexpensive, typically are not representative of native structures. This challenge can be mitigated by employing immunization strategies that use ion channel antigens that contain a native fold. For example, mAbs with blocking properties have been generated by immunizing host animals with DNA (ASIC1 (ref.
154

)
and K V 1.3 (ref.
155
)), cells expressing target ion channels (P2X7 (ref.
156
) and Orai1 (ref.
151
)), ion-channel-containing virus-like particles (P2X3 (ref.
157 )) and recombinant purified ion channels (P2X3 (ref.
147
) and K V 1.3 (ref.
)).
In an alternative approach, Quiang et al. generated a mAb that blocks ASIC1a currents with a half-maximal inhibitory concentration (IC 50 ) of 85 nM and reduces infarction in a rodent stroke model by panning a human single-chain variable fragment (scFv) combinatorial antibody phage library with nanodiscs containing reconstituted truncated ASIC1a protein; these fragments were then converted into a full-length IgG1 (ref.
159
The difficulty in discovering clinically relevant conventional ion channel mAbs has led academic and industry investigators to explore alternative modalities. For example, the variable domain of heavy-chainonly camelid antibodies, or nanobodies 160 , are small (12-15 kDa) modular immunoglobulins that can access epitopes that are difficult to reach with conventional immunoglobulins 161, 162 . Additionally, the modular nature of their small singular domains allows for somewhat straightforward engineering 161 of homomeric and heteromeric molecules to increase their potency, avidity and bispecificity and lead to half-life extension. Several examples of ion channel-modulating nano bodies, inclu ding bispecific ones, have now been described, including those targeting P2X7 and K V 1.3 (see below for further details).
Other modalities that are garnering considerable interest include KnotBodies, which incorporate cystine-knot proteins such as venom toxins 110 into the CDR of the variable domain of an antibody light chain, and antibodies that are complexed with warheads or small-molecule moieties. These fusion molecules differ from traditional antibodies for which target binding is solely CDR-driven. They represent a step forward in the development of potential ion channel therapeutics, as they combine the potency of toxins with the therapeutic advantages of mAbs. Another group of biologics for which targeting and modulating ion channel function have been largely unexplored are the Antibody-dependent cellular cytotoxicity a process in which an effector cell of the immune system (such as a natural killer cell, a macrophage, a neutrophil or an eosinophil) actively lyses a cell whose membrane surface antigens have been bound by antibodies. The crystallizable fragment (fc) portion of the antibody allows the immune cell to bind the antibody.
Complement-dependent cytotoxicity
The killing of an antibodycoated target cell via recruitment of the complement system (a set of circulating plasma proteins).
Antibody-dependent cellular phagocytosis
The engulfment of an antibody-coated cell by phagocytes such as macrophages, neutrophils or dendritic cells.
FcRn-mediated transcytosis
The neonatal crystallizable fragment (fc) receptor (fcrn) is an fc receptor that is capable of transporting immunoglobulin g (Igg) from mother's milk across the epithelium of the gastrointestinal tract or across the placenta to the fetus. binding to fcrn can be used to try and transport antibodies across epithelia.
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non-immunoglobulin protein-binding scaffolds characterized by their relatively small mass (~6-20 kDa). These include DARPins (designed ankyrin repeat proteins), affilins (derived from ubiquitin), anticalins (derived from lipocalin), atrimers (derived from tetranectin), monobodies (from fibronectin type III domains), repurposed Kunitz domains (from serine protease inhibitors) and affibodies (derived from staphylococcal protein A domain Z) 163 . As of 2015, more than 20 scaffold-derived candidates were in preclinical or clinical development, and one product, the kallikrein inhibitor ecallantide (Kalbitor), derived from a Kunitz domain, is on the market for the treatment of hereditary angioedema 163 . Although none of the identified clinical candidates targets ion channels, evidence suggests that these large and diverse scaffold libraries could provide fertile ground for identifying novel ion channel binders. For example, monobodies selected from combinatorial libraries were shown to bind and block two bacterial Fluc-type fluoride channels 164 , and high-affinity DARPins have been co-crystallized in complex with AcrB, the inner membrane pump of the Escherichia coli multidrug resistance tripartite complex AcrAB-TolC 165 .
Case study: P2X7 as a target for cancer therapy and inflammation. The lone ion-channel-targeting immunoglobulin formulation that is currently in clinical development is BIL010t 145 from Biosceptre. BIL010t is a topical therapy for basal cell carcinoma (BCC) that contains sheep polyclonal antibodies directed against a non-functional form of P2X7. This form, called nfP2X7, is a distinct conformation with a non-functional pore, is upregulated in response to the high ATP concentrations that exist in tumour microenvironments and is required for tumour cell survival 166 . Moreover, the P2X7 E200 peptide sequence (G 200 HNYTTRNILPGLNITC 216 ), whose conformation is distinct and exposed in nfP2X7 but not in wild-type P2X7, has enabled the generation of polyclonal antibodies and mAbs that selectively bind nfP2X7 on the surface of tumour cells 166 . A PEG-based topical ointment containing polyclonal antibodies purified from sheep that were repeatedly immunized with the E200 peptide conjugated to keyhole limpet haemocyanin caused a substantial reduction in the orthotopic growth of the melanoma cell line B16F10 in mice 145 . In a phase I clinical trial (NCT02587819), an ointment containing 10% BIL010t was applied to primary BCC lesions twice daily for 28 days. The treatment was well tolerated, did not result in systemic penetration of sheep polyclonal antibodies and decreased lesion size in 65% of the patients (20% showed no change, and the size increased in 15% of patients) 145 . In addition to BIL010t, Biosceptre is developing BIL03s, an anti-nfP2X7 human mAb for the treatment of solid and haematological tumours.
A mAb that targets human P2X7 was generated following immunization of mice with a stably transfected mouse myeloma cell line, XS63, that expresses human P2X7 and subsequent screening of hybridoma cell line supernatants by flow cytometry using transfected and non-transfected XS63 cells 156 . One mAb that specifically reacted with HEK cells expressing P2X7 but not P2X1 or P2X4 also recognized native P2X7 in human monocytes that had been differentiated into macrophages with lipopolysaccharide (LPS) or IFNγ. The anti-P2X7 mAb was shown to block inward currents induced by the P2X7 agonist BzATP in HEK cells transfected with human P2X7 (IC 50 ~5 nM) but not mouse or rat orthologues 156 . Anti-mouse P2X7 nanobodies with antagonistic (13A7; IC 50 12 nM) or potentiating (14D5; effective concentration for half-maximum response (EC 50 ) 6 nM) activity were isolated from phage libraries derived from llamas immunized with either HEK cells stably expressing P2X7 or with cDNA followed by a boost of P2X7-transfected HEK cells 167 . The potencies of the blocking or enhancing nanobodies increased upon multimerization. A dimeric version of 13A7 that also contains the albumin-binding nanobody Alb8 to extend serum half-life ameliorated both allergic contact dermatitis and experimental glomerulonephritis in mice 167 . Additionally, another nanobody called Dano1, which specifically recognizes human P2X7, blocked ATP-induced calcium ion influx and pore formation in P2X7-expressing HEK cells, and dimerization led to increased potency (IC 50 0.2 nM). Dano1 also inhibited inflammasome assembly in LPS-primed human monocytes as well as the shedding of CD62L and the externalization of phosphatidylserine by T cells. Interestingly, Dano1 was significantly more potent (20-fold to 50-fold) than the previously described conventional anti-P2X7 mAb 167 .
Case study: K V 1.3 as a target for autoimmune disease. In addition to the validation accompanying K V 1.3 as a therapeutic target for autoimmune disease 100, 106, 168 , its accessibility to antibodies and its presence in autoreactive T EM cells makes it a particularly attractive ion channel target for therapeutic intervention with immunoglobulins. This may explain, in part, why K V 1.3 has been a popular target for the discovery and development of immunoglobulin-based molecules among academic and biotech researchers. Polyclonal and monoclonal (conventional and nanobody) antibodies as well as KnotBodies (fIg. 3) that inhibit ion channel function and alleviate T cell-mediated autoimmune disease in animal models have been described. For example, a polyclonal antibody (E314) -purified from the sera of rabbits immunized with a 14-amino-acid peptide found in extracellular domain E3 (S5-S6 loop) of human K V 1.3 -specifically bound to HEK cells expressing K V 1.3 but not cells expressing other K V family members 169 . The E314 antibody inhibited K V 1.3 currents by approximately 90% at a concentration of 300 nM in transfected HEK cells and Jurkat T cells with no major effect on K V 1.1, K V 1.2, K V 1.4, K V 1.5 or hERG 169 . Interestingly, a K V 1. Ablynx, now a Sanofi company, has described the generation of anti-K V 1.3 nanobodies isolated from llamas using a genetic prime-boost immunization strategy. K V 1.3 nanobodies were found to be selective (10,000-fold over other K V 1 family members) and state-dependent and to have varying functional profiles. The fast onset of the functional effects strongly indicated that the nanobodies caused channel inhibition and not receptor internalization 155 . Bivalent heterodimers and homodimers were constructed, and some of the heterodimers had improved functional properties, namely increases in potencies, target residence times, avidity and duration of blockade. Additionally, a trimeric nanobody displayed higher potency in T cell-based assays. A nanobody comprising two identical anti-K V 1.3 nanobody monomers fused to an anti-albumin moiety to increase the half-life was effective in vivo in reducing ear thickness in a rat delayed hypersensitivity model 155 . More recently, conventional full-length anti-K V 1.3 mAbs have been isolated from chickens and llamas using a similar prime-boost immunization and screening strategy 158 . Chickens were immunized and boosted with purified recombinant K V 1.3 reconstituted into liposome formulations. Anti-K V 1.3 antibodies were identified and cloned following B cell screening using a gel encapsulated microenvironment assay that incorporated various K V 1.3-containing formulations, including liposomes and oriented channels adhered to magnetic beads 158 . In the case of llamas, initial immunizations were carried out with DNA and boosts with K V 1.3 liposomes. Phage libraries derived from immunized llamas were screened using K V 1.3 bound to magnetic beads. In total, 69 specific anti-K V 1.3 scFv-Fc antibodies were isolated from both animal platforms, and 10 antibodies (9 chicken and 1 llama) functionally blocked current through K V 1.3.
Characterization of select scFv-Fc clones demonstrated that the current block was both time-dependent and concentration-dependent; the most potent clone had an IC 50 of 6 nM. Antibodies showed no activity against related family members (K V 1.1, K V 1.2 and K V 1.5), hERG or Na V 1.5. epitope binning analysis revealed that, although most (seven of ten) functional antibodies segregated to one bin, suggesting a dominant functional epitope, three antibodies segregated to different bins, indicating that a functional block could be achieved through distinct epitope-binding events.
In an alternative approach, IONTAS, a company developing a KnotBody platform in which peptide toxins with a conserved inhibitory cysteine knot (knottin) structural motif are incorporated into the peripheral CDR loops of antibodies (fIg. 3) , has generated a ShK-KnotBody with a reported IC 50 of 8.6 nM for K V 1.3 inhibition 171 . Using a similar approach, a group at the Scripps Research Institute previously incorporated the K V 1.3 inhibitory scorpion peptide toxins Moka1 and Vm24-toxin into the CDR3H domain of a humanized anti-lysozyme antibody that has high structural similarity to a bovine antibody and into the CDR2H (Moka1) and CDR3L (Moka and Vm24) domains of the humanized respiratory syncytial virus-neutralizing antibody Syn 
Case study: Na V 1.7 as a target for pain. A mAb, SVmab1, with purported nanomolar potency (IC 50 31 nM), was generated in mice using a peptide that targets the Na V 1.7 S3-S4 extracellular loop region in the domain II (DII) voltage sensor 172 . SVmab1, purified from hybridoma cultures, exhibited state-dependent inhibition of Na V 1.7, 400-fold to 1,500-fold selectivity over most Na V 1.x family members, efficacy in both inflammatory and neuropathic pain models in mice and reduced scratching in both acute and chronic itch models 172 . However, a subsequent study using a recombinant form of the antibody (rSVmab), generated from published light and heavy chain antibody sequences, was unable to bind the S3-S4 antigen peptide, a soluble and purified DII voltage sensor protein or mammalian cells expressing Na V 1.7. rSVmab was also unable to specifically block Na V 1.7 current in transfected HEK293 cells 173 . Interestingly, the discoverers of SVmab confirmed the apparent discrepancies between the functional hybridoma-derived and non-functional recombinant forms of the mAb and speculated that the difference may have resulted from incorrect disclosure of antibody sequences or possibly differences in post-translational modifications of antibodies produced in hybridomas compared with transfected mammalian cells 174 . It will be of considerable interest to learn whether other researchers utilizing a similar DII voltage sensor-targeted strategy can identify mAbs with similar functional properties to SVmab.
In an approach distinct from the CDR-targeted KnotBody strategy 110 , a Na V 1.7 toxin-antibody conjugate was recently described that maintained the selective potency of the toxin warhead while extending half-life and improving biodistribution to nerve fibres 175 . In their study, Biswas et al. describe a conjugate comprising a nontargeting anti-2,4-dinitrophenol human IgG1 with a cysteine mutation at a surface residue (not in the CDRs) and replacements of proline or glycine residues attached to the tarantula venom GpTx-1 peptide toxin via a PEG 11 linker 175 . In a combinatorial approach, several factors, including cysteine mutation sites of the carrier antibody, linker chain length, conjugation chemistry and peptide loading, were evaluated for their effect on Na V 1.7 current inhibition. One antibody, conjugated at substituted cysteine E384C, exhibited a 30-fold loss in potency compared with naked peptide (IC 50 250 nM versus 8.5 nM) but had a serum half-life of 80 hours, which was about 130-fold longer than the naked peptide. Following intravenous administration, the GpTx-1 mAb conjugate biodistributed to mouse dorsal root and sciatic nerves better than the parent mAb 175 . Additionally, distribution of the conjugate to the dorsal root and sciatic nerve was substantially more pronounced in wild-type mice than in Na V 1.7-deficient mice, indicating that the presence of both Na V 1.7 and the peptide toxin was required for distribution to peripheral nerve elements across the so-called blood-nerve barrier. Although the conjugate was not effective in vivo in a mouse histamine-induced pruritus model, most likely because plasma concentrations were not sufficiently greater than measured IC 50 values, the data demonstrate that the Na V channel inhibitory properties of a toxin can be effectively combined with the desired pharmacokinetic characteristics of an antibody.
The future for ion channel antibodies In many respects, the ion channel antibody field is playing catch-up with its GPCR cousin, which boasts two marketed antibodies: the anti-CCR4 antibody mogamulizumab for the treatment of adult peripheral T cell lymphoma and an anti-CGRP receptor antibody (erenumab) for migraine. There are also at least 15 other GPCR-targeting immunoglobulins in various phases of clinical development and more projects at the preclinical stage 19 . The challenges associated with developing GPCR antibodies have been described in detail elsewhere 19, 176, 177 ; suffice it to say, in cases where functional antibodies are desirable, the GPCR and the ion channel fields face the same difficulties in developing antibodies that recognize specific conformational states of the target protein (the active versus the inactive state of a GPCR or the open versus the inactivated state of an ion channel; see fIg. 1a). However, attributing the discrepancy in the current development status of GPCR and ion channel antibodies to the comparative difficulty of targeting ion channels versus GPCRs would not sufficiently acknowledge the substantial advancements made in the GPCR field. These include technologies such as the stabilized receptor (StaR) technology, in which a few point mutations are introduced into a GPCR to improve its thermostability without disrupting its pharmacology 178, 179 . Heptares Therapeutics is using this technology not only to generate protein samples for X-ray crystallography and small-molecule screening but also to enable purification of high quality, functional and monodisperse protein samples that can be incorporated into effective antigen and screening formulations for both in vivo immunization and in vitro antibody discovery platforms. Instead, the proliferation of clinical antibody candidates during the past 10 years against a difficult class of membrane proteins like GPCRs should provide a level of optimism that similar advancements in ion channels are also within reach.
Overcoming the aforementioned challenges for advancing the ion channel antibody pipeline will undoubtedly involve integrating next-generation platforms into the discovery process. For example, limitations of traditional approaches such as hybridoma screening, in which non-efficient fusion events and subsequent loss of rare B cells can impact immune diversity 180 , can be mitigated by technologies that incorporate direct B cell cloning, thereby enabling the identification of rare clones and the recovery of natively paired light and heavy chain genes 119 . Similarly, traditional display technologies such as phage display and yeast display are being further enhanced by next-generation sequencing, which allows up to 10,000 times more sequences to be analysed than the Sanger method did and thus enables deeper interrogation of library diversity and the identification of rare clones 181, 182 . Parallel advances in recombinant ion channel production, using alternative expression hosts (for example, Tetrahymena thermophila), cell-free systems and non-detergent-based purification methods and formulations, have increased the quality (native fold) and quantity (more than milligrams) of purified protein. These existing advances and the future development of protocols to enable the production of stable, state-specific channels will likely complement new approaches to antibody discovery and therefore increase the chances of recovering antibodies with desired properties. With nanobodies, it might even be feasible to target intracellular ion channel domains (box 2).
Perspectives and concluding remarks Ion channel drug discovery and development are approaching a crossroad, where future breakthroughs and new products are likely to increasingly rely on biologic modalities that arise from technical advances in peptides, antibodies and hybrid molecules. Given the diversity of approaches and the current speed of innovation across academia and the pharmaceutical industry, it is difficult to pinpoint exactly which therapeutic areas will gain most quickly and substantially from this development, but accessibility of the cellular targets will likely be key. Because injected peptides and antibodies usually have quite low volumes of distribution, meaning that they tend to stay in the bloodstream rather than penetrating deeply into tissues and cells, it is likely that haematological diseases, certain types of cancer and immune diseases are the most straightforward therapeutic areas, whereas CNS diseases are much more challenging owing to the tight BBB. This view is supported by the observation that, for therapeutic antibodies targeting extracellular proteins, peripheral anti-cytokine therapy is an established and successful treatment for autoimmune diseases, but attempts to treat Alzheimer disease with antibodies against amyloid-β are lagging behind. That said, between these extremes, there are many opportunities in organs with loose or non-existent endothelial barriers (for example, bone marrow and liver) that are accessible using local administration (for example, lungs and skin) or by administration via specific routes (for example, intrathecal) or even by exploiting uptake across disease-damaged barriers, such as the BBB in stroke or the intestinal epithelium in inflammatory bowel diseases. In considering the ion channel targets themselves, channels with prominent extracellular loops (like GABA A receptors, nACh receptors and P2X receptors or K 2P channels) are thought to be more tractable by antibodies than channels with restricted extracellular exposure are. However, as discussed in this Review, it is indeed possible to generate function-blocking antibodies against ion channels with limited extracellular epitopes (for example, K V 1.3 and Orai).
Although the field of ion channel-targeted biologics can, at the moment, boast only one therapy -the intrathecally administered Ca V 2.2-blocking peptide ziconotide -in the clinic and one polyclonal antibody and three peptides in clinical trials, we believe that this field is very likely to develop and expand in the next decade (for a recent comprehensive review on ion channels as antibody targets see ref.
198
). It is currently hard to predict whether venom-derived peptides or antibodies will be more successful. Peptide design is currently benefiting tremendously from advances in ion channel structural determination and molecular modelling, which together are enabling structure-based or at least structure-assisted peptide design. 'Naked' peptides typically have short circulating half-lives and, depending on whether they are intended for acute or chronic use, might require some of the half-life-extending modifications or formulation approaches described here to be considered suitable for clinical development. For traditional mAbs, the main challenges, in our opinion, will be to select the most suitable ion channel targets and then tailor the antibody
Box 2 | Targeting ion channel cytoplasmic epitopes with nanobodies
Immunoglobulins are not able to passively access the cell cytoplasm. Therefore, ion channel antibody discovery programmes, like those directed towards other cell surface molecules, are generally designed to identify antibodies that recognize extracellular epitopes and exert their functional effects through a steric or allosteric block or by removing the channel from the cell surface by internalization mechanisms. Consequently, intracellular epitopes, which constitute a considerably larger area than that displayed on the surface for many voltagegatedlike ion channels (for example, approximately 70% of the calciumand sodiumactivated potassium channel K Na 1.1 is intracellular), are left untargeted. In a recent review, Ingram et al. 162 highlighted the attributes of nanobodies that may allow the cytosolic side of membrane proteins, such as G proteincoupled receptors (GPCRs) or ion channels, to be exploited for basic research, immunodiagnostics and potentially for therapeutic intervention.
Nanobodies are single domain antibodies comprising the variable domain of camelid immunoglobulin G (IgG) molecules, known as vHH. They are small (~15 kDa) and modular in nature, bind their targets with affinities similar to those for conventional antibodies 186 and tend to recognize epitopes in clefts of protein surfaces or at protein interaction interfaces 187 . like conventional antibody light and heavy chain variable domains, nanobody antigen binding is driven by three complementaritydetermining regions (CDRs). However, unlike conventional antibodies, which require disulfide paired light and heavy chain variable domains to form a paratope 188 , nanobodies form paratopes from a single domain. Therefore, unlike conventional antibodies, nanobodies maintain target specificity in reducing environments (such as the cytoplasm).
Cytosolic expression of nanobodies has been exploited in a number of phenotypic screens to identify functional hits and further explore cellular processes. In one example, a randomized vHHCDR3 intracellular antibody library was introduced into highly metastatic human fibrosarcomaderived cells followed by iterative rounds of cell migration assays to identify clones associated with nonmigrating cells 189 . using this approach, one nanobody clone identified that heterogenous nuclear ribonucleoprotein K (hnRNPK) has a role in metastasis 189 . In another instance, vHH coding sequences derived from alpacas immunized with inactivated influenza A virus (IAv) or vesicular stomatitis virus (vSv) were cloned into a lentiviral vector and used in a phenotypic screen to identify intracellularly expressed nanobodies that protected human A549 cells from lethal infection with either IAv or vSv 190 . In addition to phenotypic screens, nanobodies have been engineered to selectively degrade target molecules via ubiquitylation by fusing the nanobodies to ubiquitin ligase F box subunits 191, 192 . Nanobodies have also served as chaperones that bind to the intracellular surface of GPCRs, such as the β 2 adrenoceptor and acetylcholine muscarinic m 2 receptors, to stabilize active conformations and enable structural determination by Xray crystallography 193, 194 . It remains to be determined whether targeting intracellular domains of ion channels with nanobodies will provide the same molecular insights into stabilized state dependent structures as it has with GPCRs and whether expression of antiion channel nanobodies can be used therapeutically to functionally disrupt or induce the degradation of ion channels. Nevertheless, the propensity for nanobodies to recognize epitopes in protein-protein interfaces raises the intriguing possibility of investigating the biological mechanisms of ion channel complexes. The α subunit that makes up the ion channel pore is typically only one of a number of regulatory and auxiliary proteins that influences channel function, trafficking, distribution and signalling. Indeed, several channelopathies are associated with mutations that disrupt ion channel complex formation and cause cardiac arrhythmias 195 . Induced expression of nanobodies raised against ion channel interaction domains may help deconvolute complex formation under varying physiological conditions, illuminate the precise temporal and spatial role of complex components and possibly identify novel targets for therapeutic intervention. New insight into the cytosolic face of ion channel biology may simply await the design of elegant phenotypic screens that utilize intracellular nanobody libraries as described above.
www.nature.com/nrd characteristics to the desired therapeutic effect (for example, inhibition or activation of channel function, channel internalization and induction of target cell apoptosis) by engineering the antibody to fit the pathophysiology of the target disease. The BIL010t antibody against a non-functional form of P2X7 that is required for tumour cell survival 166 and discussed above is a perfect illustration of a very clever topical use of a polyclonal sheep antibody for BCC in which the characteristics of the antibody seem to meet the medical need.
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